"Men are so simple, and so much creatures of circumstance, that the deceiver will always find somebody ready to be deceived.”
-- Niccolò Machiavelli
Recent JNJ News
- Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference • Business Wire • 10/10/2024 08:30:00 PM
- TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis • PR Newswire (US) • 10/10/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 09:07:15 PM
- Johnson & Johnson Completes Acquisition of V-Wave • Business Wire • 10/09/2024 12:00:00 PM
- Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference • Business Wire • 10/04/2024 08:30:00 PM
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • InvestorsHub NewsWire • 10/03/2024 12:45:00 PM
- ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer • PR Newswire (US) • 10/02/2024 01:00:00 PM
- Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned • PR Newswire (US) • 09/30/2024 08:05:00 PM
- Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting • PR Newswire (US) • 09/30/2024 12:05:00 PM
- CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line • PR Newswire (US) • 09/27/2024 08:30:00 PM
- DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma • PR Newswire (US) • 09/27/2024 05:05:00 PM
- DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned • PR Newswire (US) • 09/27/2024 05:00:00 PM
- Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary dise • PR Newswire (US) • 09/27/2024 12:05:00 PM
- TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma • PR Newswire (US) • 09/27/2024 12:00:00 PM
- Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More • IH Market News • 09/23/2024 10:32:25 AM
- Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt • Business Wire • 09/20/2024 10:53:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:19:26 PM
- Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims • Business Wire • 09/20/2024 07:43:00 PM
- RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/19/2024 10:54:00 PM
- Microsoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with Amazon • IH Market News • 09/17/2024 10:40:35 AM
- Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer • PR Newswire (US) • 09/16/2024 06:50:00 AM
- New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 09/15/2024 06:30:00 AM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer • PR Newswire (US) • 09/14/2024 01:45:00 PM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer • PR Newswire (US) • 09/14/2024 07:10:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:44:56 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM